Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
16 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/16/3206076/0/en/BPGbio-Announces-Publication-of-Pioneering-Solid-Tumor-Study-with-BPM31510-IV-using-Patient-Omics-and-Bayesian-AI-to-Guide-Clinical-Development.html
11 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/12/3185849/0/en/BPGbio-Appoints-John-Dvor-as-Executive-Vice-President-Corporate-Development.html
20 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/20/3169226/0/en/BPGbio-and-Icahn-School-of-Medicine-at-Mount-Sinai-Publish-Landmark-Study-on-the-Living-Human-Brain-Unlocking-New-Molecular-Insights-Into-Neurodegenerative-Disease.html
16 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/16/3167784/0/en/BPGbio-Presents-Phase-2-Glioblastoma-Data-on-BPM31510-at-ESMO-2025.html
14 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/14/3166000/0/en/BPGbio-Welcomes-Sheikh-Dr-Khalid-Bin-Jabor-Al-Thani-as-Executive-in-Residence.html
06 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/06/3161920/0/en/BPGbio-Appoints-Veteran-Clinical-and-Commercial-Leader-Dr-Brian-Berman-as-Interim-Chief-Medical-Officer.html
Drugs in Development
Details:
BPM31510T (benzoquinone ubidecarenone) is an investigational treatment for epidermolysis bullosa (EB), received Rare Pediatric Disease Designation for respective indication.
Lead Product(s): Ubidecarenone
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 31, 2024
Lead Product(s) : Ubidecarenone
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BPGbio Receives FDA Pediatric Disease Designation for Epidermolysis Bullosa Treatment
Details : BPM31510T (benzoquinone ubidecarenone) is an investigational treatment for epidermolysis bullosa (EB), received Rare Pediatric Disease Designation for respective indication.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 31, 2024
Details:
The collaboration aims to develop novel protein degraders to deliver groundbreaking therapeutic candidates for particularly in oncology and central nervous system (CNS) diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Sponsor: University of Oxford
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 07, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : University of Oxford
Deal Size : Undisclosed
Deal Type : Collaboration
BPGbio and University of Oxford Partner on E2-Based Protein Degradation Research
Details : The collaboration aims to develop novel protein degraders to deliver groundbreaking therapeutic candidates for particularly in oncology and central nervous system (CNS) diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 07, 2024
Details:
BPM31510IV (benzoquinone ubidecarenone) works by restoring CoQ10 levels which can overcome the effect of mutations in genes that lead to mitochondrial dysfunction, in primary CoQ10 deficiency.
Lead Product(s): Benzoquinone Ubidecarenone
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Enzyme
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2024
Lead Product(s) : Benzoquinone Ubidecarenone
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BPGbio Gets FDA Pediatric Designation for Coenzyme Q10 Deficiency Drug
Details : BPM31510IV (benzoquinone ubidecarenone) works by restoring CoQ10 levels which can overcome the effect of mutations in genes that lead to mitochondrial dysfunction, in primary CoQ10 deficiency.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
September 30, 2024
Details:
BPM 31510, the company’s lead drug candidate, acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.
Lead Product(s): Ubidecarenone,Temozolomide,Vitamin K1
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Berg Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 06, 2023
Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Berg Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BPM 31510, the company’s lead drug candidate, acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 06, 2023
Details:
The collaboration is for BPGbio’s BPM 31510 for Epidermolysis Bullosa Phase II/III trial. Debra of America will provide support to awareness, understanding, and key information towards patient recruitment and advocacy for the clinical trial.
Lead Product(s): Ubidecarenone
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Debra of America
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 27, 2023
Lead Product(s) : Ubidecarenone
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Debra of America
Deal Size : Undisclosed
Deal Type : Partnership
Details : The collaboration is for BPGbio’s BPM 31510 for Epidermolysis Bullosa Phase II/III trial. Debra of America will provide support to awareness, understanding, and key information towards patient recruitment and advocacy for the clinical trial.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
March 27, 2023
Details:
BPM31510 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.
Lead Product(s): Coenzyme Q10,Vitamin K1,Temozolomide
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2021
Lead Product(s) : Coenzyme Q10,Vitamin K1,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Details : BPM31510 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 12, 2021
Details:
BPM31510 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Coenzyme Q10
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 26, 2016
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
Details : BPM31510 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 26, 2016
Details:
BPM31510 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epidermolysis Bullosa.
Lead Product(s): Coenzyme Q10
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Shasa Hu
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 08, 2016
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Shasa Hu
Deal Size : Inapplicable
Deal Type : Inapplicable
Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa
Details : BPM31510 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epidermolysis Bullosa.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 08, 2016
Details:
BPM31510 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Lead Product(s): Coenzyme Q10,Gemcitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 08, 2016
Lead Product(s) : Coenzyme Q10,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
Details : BPM31510 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 08, 2016
Details:
BPM31510 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Coenzyme Q10
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 01, 2015
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
Details : BPM31510 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 01, 2015
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
